TrialCancer medicine2012

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.

John Arcaroli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.